Showing results (141-150 of 216) with videos related to
Sort By:
Pageof 22
AIDS and Behavior|March 22, 2021
HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and ChallengesSabrina A Assoumou, Samantha M Paniagua, Priscilla Gonzalez, et al.JAMA Network Open|April 14, 2023
Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in MassachusettsAvik Chatterjee, Michelle Weitz, Alexandra Savinkina, et al.Sexually Transmitted Diseases|October 27, 2018
Rapid Syphilis Testing for Men Who Have Sex With Men in Outreach Settings: Evaluation of Test Performance and Impact on Time to TreatmentOluyomi A Obafemi, Karen A Wendel, Teri S Anderson, et al.Health Affairs (Project Hope)|September 11, 2013
The cost of overtriage: more than one-third of low-risk injured patients were taken to major trauma centersCraig D Newgard, Kristan Staudenmayer, Renee Y Hsia, et al.Open Forum Infectious Diseases|February 3, 2022
Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US CityKevin F Kamis, David L Wyles, Matthew S Minturn, et al.Addiction (Abingdon, England)|March 22, 2022
Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programsJoëlla W Adams, Alexandra Savinkina, Aaron Fox, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 13, 2017
Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United StatesElena Losina, Emily P Hyle, Ethan D Borre, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.JAMA Network Open|February 28, 2022
Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-Associated Infective EndocarditisJoëlla W Adams, Alexandra Savinkina, James C Hudspeth, et al.Journal of Substance Use and Addiction Treatment|September 19, 2024
An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorderMathieu Castry, Yjuliana Tin, Noah M Feder, et al.Pageof 22